Results from Phase 2 clinical study showed patients with cocaine use disorder (CUD) who were treated with Omeros� $OMER OMS405 experienced a drastic time-dependent reduction in cocaine craving compared to placebo. The trial was conducted at the Center for Neurobehavioral Research on Addition, University of Texas Health Science Center in Houston.